Introduction
Methods
Data source
Patient selection and analysis
Statistical analysis
Multivariate analysis
Predictive models
Results
Demographics
Complications
30-day readmission (n = 1,630,578) | 90-day readmission (n = 1,367,850) | 180-day readmission (n = 979,040) | 300-day readmission (n = 371,804) | |
---|---|---|---|---|
Primary | ||||
Constipation | 157,852 (9.7%) | 131,477 (9.6%) | 92,266 (9.4%) | 34,555 (9.3%) |
IBS | 16,655 (1.0%) | 13,973 (1.0%) | 9,736 (1.0%) | 3,741 (1.0%) |
Crohn’s disease | 4,860 (0.3%) | 4,153 (0.3%) | 2,934 (0.3%) | 1,141 (0.3%) |
Ulcerative colitis | 5,121 (0.3%) | 4,262 (0.3%) | 2,995 (0.3%) | 1,179 (0.3%) |
Gastrointestinal hemorrhage | 20,931 (1.3%) | 17,593 (1.3%) | 13,065 (1.3%) | 5,084 (1.4%) |
UTI | 335,252 (20.6%) | 280,983 (20.5%) | 201,352 (20.6%) | 78,874 (21.2%) |
Urinary retention | 83,905 (5.1%) | 69,216 (5.1%) | 48,509 (5.0%) | 18,248 (5.0%) |
Anti-parkinsonism drug effect | 20,534 (1.3%) | 17,800 (1.3%) | 12,945 (1.3%) | 5,194 (1.4%) |
Readmission | ||||
Readmission rate | 200,078 (12.3%) | 349,007 (25.5%) | 355,591 (36.3%) | 170,424 (45.8%) |
Blood transfusion | 17,315 (8.7%) | 30,110 (8.6%) | 29,571 (8.3%) | 14,146 (8.3%) |
Odds ratio | 95% confidence interval | p-value | |
---|---|---|---|
30-day readmission | |||
Constipation | 0.99 | 0.99–1.00 | 0.09 |
IBS | 0.99 | 0.98–1.01 | 0.55 |
Crohn’s disease | 1.03 | 0.99–1.06 | 0.10 |
Ulcerative colitis | 1.02 | 0.99–1.05 | 0.21 |
Gastrointestinal hemorrhage | 1.14 | 1.13–1.16 | < 0.0001* |
UTI | 1.00 | 0.99–1.00 | 0.74 |
Urinary retention | 1.00 | 1.00–1.01 | 0.25 |
Anti-parkinsonism drug effect | 1.06 | 1.04–1.08 | < 0.0001* |
90-day readmission | |||
Constipation | 0.99 | 0.989–0.999 | 0.0045*
|
IBS | 0.99 | 0.97–1.00 | 0.07 |
rohn’s disease | 1.04 | 1.01–1.06 | 0.008* |
Ulcerative colitis | 1.02 | 1.01–1.05 | 0.046* |
Gastrointestinal hemorrhage | 1.16 | 1.14–1.17 | < 0.0001* |
UTI | 1.00 | 1.00–1.01 | 0.14 |
Urinary retention | 1.00 | 0.99–1.00 | 0.57 |
Anti-parkinsonism drug effect | 1.07 | 1.06–1.09 | < 0.0001* |
180-day readmission | |||
Constipation | 1.00 | 0.99–1.00 | 0.08 |
IBS | 0.98 | 0.970–0.997 | 0.02* |
Crohn’s disease | 1.03 | 1.01–1.06 | 0.009* |
Ulcerative colitis | 1.02 | 0.99–1.04 | 0.20 |
Gastrointestinal hemorrhage | 1.14 | 1.13–1.16 | < 0.0001* |
UTI | 1.00 | 1.00–1.01 | 0.12 |
Urinary retention | 1.00 | 0.99–1.00 | 0.27 |
Anti-parkinsonism drug effect | 1.05 | 1.04–1.07 | < 0.0001* |
300-day readmission | |||
Constipation | 0.99 | 0.985–0.998 | 0.008* |
IBS | 0.99 | 0.97–1.01 | 0.18 |
Crohn’s disease | 1.04 | 1.01–1.08 | 0.04* |
Ulcerative colitis | 1.02 | 0.99–1.06 | 0.21 |
Gastrointestinal hemorrhage | 1.12 | 1.11–1.14 | < 0.0001* |
UTI | 1.00 | 1.00–1.01 | 0.66 |
Urinary retention | 1.00 | 0.99–1.01 | 0.54 |
Anti-parkinsonism drug effect | 1.06 | 1.04–1.08 | < 0.0001* |